Among our validated tumor suppressor hits, Rbm25 KD yielded the most prominent effect on Lp30 AML cells compared to c-Kit+ control cells (Fig. 1d, e, see Supplementary Fig. 1h and i for the KD efficiency of all four shRNAs in the library), and we therefore forwarded RBM25 for functional analysis. The gene discussed is KIT; the disease is acute myeloid leukemia.